Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558893 · ClinicalTrials.gov registry record
Sleep and Circadian Mechanisms of Non-dipping Blood Pressure
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 30
- Enrollment target
NCT03558893: Completed study, sponsored by Oregon Health and Science University.
NCT03558893 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03558893 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study will be the first to distinguish the relative contributions of sleep, circadian and behavioral mechanisms to the non-dipping BP profile in Black adults and will lay the groundwork for optimizing therapies dependent on mechanisms, such as targeting sleep, targeting circadian rhythmicity, or targeting behaviors, and raising the possibility that ideal therapy for hypertension (HTN) may differ by race. This research will ultimately help to improve health and survival in black populations with HTN.
Primary Outcome
Systolic blood pressure measured via automatic sphygmomanometer every 30 minutes during sleep period at baseline. Readings recorded in units of mmHg.
Interventions
- BEHAVIORAL Forced Desynchrony
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2024-12-31 |
What the finished NCT03558893 record still lists
NCT03558893 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Forced Desynchrony is the first listed.
NCT03558893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03558893 about?
NCT03558893 is a clinical study titled "Sleep and Circadian Mechanisms of Non-dipping Blood Pressure". This study will be the first to distinguish the relative contributions of sleep, circadian and behavioral mechanisms to the non-dipping BP profile in Black adults and will lay the groundwork for optimizing therapies dependent on mechanisms, such as targeting sleep, targeting circadian rhythmicity, o...
What is the current status of trial NCT03558893?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-12-01. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT03558893?
The interventions under investigation include: Forced Desynchrony (BEHAVIORAL).
Who is sponsoring clinical trial NCT03558893?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI